One molecule after the other is hitting the market ... it's a different play or adalimumab, by the way, we also said that on that one, we are going down a different route. We are doing private ...

The group has an exclusive license to market this patented molecule developed by Dong-A ... company in the world to launch the biosimilar of Adalimumab - the worlds largest selling therapy.

Researchers at Umeå University, Sweden, and Michigan State University, U.S., have discovered a type of molecule that can kill chlamydia bacteria, but spare bacteria that are important for health.

Hidradenitis suppurativa (HS) is a refractory and recurrent chronic inflammatory skin disease characterized by nodules, abscesses, sinus tracts, and scarring. The etiology of HS remains unclear, ...

The three platform deals are long-term bets, but broaden Genentech’s drug discovery capabilities, particularly in small-molecule R&D. The Convelo deal focuses on the development of novel drug ...

BenevolentAI has entered a two-year agreement with the MRC Technology to investigate new small molecule and antibody drug candidates. The UK-based artificial intelligence company has teamed up ...

Biocon is preparing for a year of strong momentum in 2025-26 (FY26), led by major upcoming launches across its generics and biosimilars portfolio. Siddharth Mittal, MD & CEO, said the company is ...

Clinical and Radiographic Outcomes of Four Different Treatment Strategies in Patients With Early Rheumatoid Arthritis (the Best Study): A Randomized, Controlled Trialfrom Arthritis & Rheumatism ...

Although there’s not much evidence to support it, a treat-to-target approach is strongly recommended for patients who haven’t taken biologics or small molecule drugs. In treat-to-target, doctors and ...